Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800782 | 0.82 | ICMT (0.37) | CAPN1ALDH1A1KDM4EHTTICMT | |
| SCHEMBL22800780 | 0.76 | ICMT (0.37) | CAPN1ALDH1A1KDM4EHTTICMT | |
| SCHEMBL22800194 | 0.71 | CAPN1 (0.47) | CAPN1KDM4EICMTHPGDMEN1 | |
| SCHEMBL13180284 | 0.67 | MEN1 (0.53) | ALDH1A1KDM4EHTTLMNAPKM | |
| SCHEMBL22800135 | 0.65 | CAPN1 (0.49) | CAPN1ICMT | |
| SCHEMBL28715040 | 0.63 | MEN1 (0.47) | ALDH1A1KDM4EHTTLMNAHPGD | |
| SCHEMBL14009429 | 0.62 | PTK2 (0.46) | ALDH1A1KDM4EHTTLMNAHPGD | |
| SCHEMBL22799711 | 0.61 | CAPN1 (0.47) | CAPN1ALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL22799717 | 0.61 | CAPN1 (0.47) | CAPN1KDM4EHTTHPGDMEN1 | |
| SCHEMBL25271329 | 0.61 | MEN1 (0.45) | ALDH1A1KDM4EHTTLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | CAPN1 3/4885ALDH1A1 3918/4885KDM4E 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.